Vascular dementia (VaD) is a common disorder which currently lacks definitive treatments. Cerebrolysin, a peptide preparation produced from purified pig brain proteins, seems to be a promising intervention based on animal studies and clinical trials in other conditions. We identified six trials involving 597 participants suitable for inclusion in this review. Pooled results showed improvements in cognitive function and global function in patients with VaD of mild to moderate severity, with no obvious side effects related to Cerebrolysin. However, due to the limited number of included trials, varying treatment durations and short-term follow-up, there is insufficient evidence to recommend Cerebrolysin as a routine treatment for patients with VaD.
Cerebrolysin for vascular dementia
31 January 2013
More like this
- Rivastigmine appears to moderately improve cognition and to a lesser extent activities of daily living in patients with PDD
- Melatonin treatment may be effective for the treatment of dementia-related behavior disturbances
- No evidence from randomised controlled trials for or against the use of Zhiling concoction in the treatment of people with vascular dementia
- There is currently no high quality evidence to support the use of Huperzine A for the treatment of vascular dementia.
- There is no evidence from randomised controlled trials for or against the use of 'Yizhi capsule' as a treatment for vascular dementia